Xatryx

Xatryx is a clinical-stage biotechnology company dedicated to developing transformative B-cell depleting therapies for patients suffering from severe autoimmune and inflammatory diseases. The company's lead therapeutic candidate, XAT-101, is a monoclonal antibody designed to target CD19, a protein expressed across a broad range of the B-cell lineage. By targeting CD19 rather than the more common CD20, Xatryx aims to achieve deeper and more comprehensive depletion of pathogenic B cells, including those in tissues and early-stage precursors. Currently in early clinical development, XAT-101 is being evaluated for indications such as systemic lupus erythematosus (SLE) and myasthenia gravis. Based in San Diego, Xatryx is supported by a syndicate of premier life science investors and led by an experienced management team with a focus on precision immunology.